CA3075649A1 - A novel small molecule compound - Google Patents

A novel small molecule compound Download PDF

Info

Publication number
CA3075649A1
CA3075649A1 CA3075649A CA3075649A CA3075649A1 CA 3075649 A1 CA3075649 A1 CA 3075649A1 CA 3075649 A CA3075649 A CA 3075649A CA 3075649 A CA3075649 A CA 3075649A CA 3075649 A1 CA3075649 A1 CA 3075649A1
Authority
CA
Canada
Prior art keywords
disease
cancer
cpt
mitochondrial
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3075649A
Other languages
English (en)
French (fr)
Inventor
Bingwei Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerepeut LLC
Original Assignee
Cerepeut LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerepeut LLC filed Critical Cerepeut LLC
Publication of CA3075649A1 publication Critical patent/CA3075649A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA3075649A 2017-09-13 2018-09-12 A novel small molecule compound Pending CA3075649A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558323P 2017-09-13 2017-09-13
US62/558,323 2017-09-13
PCT/US2018/050689 WO2019055528A1 (en) 2017-09-13 2018-09-12 NEW COMPOUND WITH SMALL MOLECULES

Publications (1)

Publication Number Publication Date
CA3075649A1 true CA3075649A1 (en) 2019-03-21

Family

ID=65723058

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3075649A Pending CA3075649A1 (en) 2017-09-13 2018-09-12 A novel small molecule compound

Country Status (9)

Country Link
US (3) US11186550B2 (enExample)
EP (1) EP3681874B1 (enExample)
JP (1) JP7170341B2 (enExample)
KR (1) KR102644045B1 (enExample)
CN (1) CN111372921B (enExample)
AU (1) AU2018331371C1 (enExample)
CA (1) CA3075649A1 (enExample)
IL (1) IL273242B2 (enExample)
WO (1) WO2019055528A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12454514B2 (en) 2019-02-27 2025-10-28 Cerepeut, Inc. Quinazolinone compounds

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102644045B1 (ko) 2017-09-13 2024-03-05 셀리퓨트, 인코포레이티드 신규한 소분자 화합물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060011785A (ko) * 2002-06-27 2006-02-03 디 인다우먼트 포 리써치 인 휴먼 바이올로지, 인크. Ａｌｄｈ 억제에 유용한 화합물
US20050038051A1 (en) 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
CA2620248A1 (en) * 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co. Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
US8759097B2 (en) 2011-04-19 2014-06-24 University of Pittsburgh—of the Commonwealth System of Higher Eduction Inhibition of dynamin related protein 1 to promote cell death
US9492450B2 (en) * 2011-04-19 2016-11-15 University of Pittsburgh—of the Commonwealth System of Higher Education Inhibition of dynamin related protein 1 to promote cell death
JP2013142070A (ja) * 2012-01-11 2013-07-22 Nihon Univ ミトコンドリア分裂阻害剤を用いたｔｒａｉｌ抵抗性の克服
CN105008515A (zh) 2012-12-28 2015-10-28 小利兰·斯坦福大学托管委员会 用于治疗线粒体疾病和用于使细胞分化成神经元的组合物和方法
US9289448B2 (en) 2013-03-15 2016-03-22 Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treating alzheimer's disease and other tauopathies
US9730935B2 (en) 2013-12-13 2017-08-15 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment
GB201522232D0 (en) * 2015-12-16 2016-01-27 Liverpool School Tropical Medicine Combination product
KR102644045B1 (ko) 2017-09-13 2024-03-05 셀리퓨트, 인코포레이티드 신규한 소분자 화합물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12454514B2 (en) 2019-02-27 2025-10-28 Cerepeut, Inc. Quinazolinone compounds

Also Published As

Publication number Publication date
JP2020533399A (ja) 2020-11-19
US11186550B2 (en) 2021-11-30
US20200216400A1 (en) 2020-07-09
AU2018331371B2 (en) 2024-02-15
EP3681874A4 (en) 2021-01-13
JP7170341B2 (ja) 2022-11-14
IL273242A (en) 2020-04-30
AU2018331371A1 (en) 2020-04-02
CN111372921B (zh) 2023-12-01
IL273242B1 (en) 2023-04-01
US20220340534A1 (en) 2022-10-27
EP3681874B1 (en) 2022-04-06
KR20200053560A (ko) 2020-05-18
US11912669B2 (en) 2024-02-27
EP3681874A1 (en) 2020-07-22
IL273242B2 (en) 2023-08-01
US20240246919A1 (en) 2024-07-25
WO2019055528A1 (en) 2019-03-21
US12404251B2 (en) 2025-09-02
KR102644045B1 (ko) 2024-03-05
CN111372921A (zh) 2020-07-03
AU2018331371C1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
US12404251B2 (en) Small molecule compound
CN102333752A (zh) 氧杂二环庚烷与氧杂二环庚烯、它们的制备及应用
CA3234750A1 (en) Modulators of sestrin-gator2 interaction and uses thereof
US20210085649A1 (en) Methods and use of compounds that bind to rela of nf-kb
JPH08502488A (ja) 前立腺癌および初期神経悪性疾患に対するベンゾキノイドアンサマイシンの殺腫瘍活性
US20240355686A1 (en) Clinical Methods and Pharmaceutical Compositions Employing AMPA Receptor Antagonists to Treat Glioblastoma and Other Cancers
CN109310650A (zh) 用于减少过表达c-myc的癌症中的c-myc的化合物
US12454514B2 (en) Quinazolinone compounds
US20240382509A1 (en) Cannabinoids C- and O-glycosides possessing anti-proliferative and anti-metastatic properties and process for preparation thereof
TWI542348B (zh) 含４－乙醯基－安卓奎諾－ｂ之組合物用於製備抑制癌細胞生長之藥物的用途
CN100415219C (zh) 取代的二环[3.3.1]壬烷-2,4,9三酮作为活性药物成分
KR20030085421A (ko) ｐ53 또는 ｐ21 유전자 변이에 의해 ｐ53 또는 ｐ21유전자 기능을 상실한 암의 치료를 위한 액틴 저해제를포함하는 약학 조성물
CN112999236B (zh) 乌本苷用于治疗脑干胶质瘤的用途
HK40086108A (en) Modulators of sestrin-gator2 interaction and uses thereof
HK1251486B (en) Modulators of sestrin-gator2 interaction and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230907